A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies
This study is testing a new experimental medicine called RSC-1255, either by itself or combined with another drug, to see how safe it is and how well it works. It is designed for adults with advanced solid tumor cancers like lung, colon, pancreatic, or certain brain tumors that have not responded to standard treatments.
You might be able to join if you have an advanced cancer with a specific genetic change called a RAS mutation, and standard treatments have stopped working or you could not tolerate them. Participants must also be free of other serious medical conditions like major heart or liver issues.
You will receive the study drug, RSC-1255, while doctors carefully monitor your health and safety. The first part of the study helps figure out the best dose, and the second part tests that dose in more patients.
This study is currently recruiting participants at multiple locations including Los Angeles, California, Denver, Colorado, and Nashville, Tennessee.
- 1Testing a new cancer drug called RSC-1255 for advanced solid tumors
- 2Open to adults whose standard cancer treatments have not worked
- 3Currently actively recruiting patients at multiple US locations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.